Form 4: EcoR1 Capital Increases Stake in Atara Biotherapeutics
Statement of Changes in Beneficial Ownership
EcoR1 Capital, LLC reported the acquisition of 507,407 shares of Atara Biotherapeutics, Inc. common stock.
Summary
- EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., acquired 507,407 shares of Atara Biotherapeutics (ATRA).
- The shares were purchased at a weighted average price of $9.35 per share.
- The transaction occurred on May 7, 2026.
- Following this acquisition, the reporting persons beneficially own 1,552,000 shares of Atara Biotherapeutics.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive signal, as it reflects a significant capital commitment from a sophisticated healthcare-focused investment firm.
Positives
- Significant increase in equity position by a major institutional investor (EcoR1 Capital).
- Demonstrates confidence from a specialized healthcare investment firm in the issuer's long-term prospects.
Negatives
- None identified in this filing.
Risks
- Market volatility affecting the value of the acquired shares.
- General risks associated with biotechnology investments and clinical trial outcomes.
Future Outlook
No specific forward-looking guidance provided in this ownership disclosure.
Industry Context
StockSavvy.ai notes that institutional accumulation by specialized biotech funds like EcoR1 often signals a positive outlook on the company's clinical pipeline or upcoming data readouts.
Comparison to Industry Standards
- The acquisition aligns with standard institutional investment behavior in the small-cap biotech sector.
- EcoR1 Capital is a known specialist in the life sciences sector, making this a strategic rather than passive investment.
Related Party Transactions
- The filing discloses that EcoR1 Capital, LLC acts as the investment adviser to the funds involved in the transaction.
Stakeholder Impact
- Shareholders may view this as a vote of confidence in the company's current valuation and future potential.
Next Steps
- Continued monitoring of SEC filings for further changes in beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 05/07/2026 | Date of the reported share acquisition transaction. |
| 05/11/2026 | Date of the filing signature. |
Keywords
Atara Biotherapeutics, EcoR1 Capital, ATRA, Insider Trading, Biotech, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.